Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL23R | Q5VWK5 | 2/20 | 0.52 |
| ▸ | BACE1 | P56817 | 1/20 | 0.52 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.52 |
| ▸ | KISS1R | Q969F8 | 4/20 | 0.52 |
| ▸ | VIPR2 | P41587 | 4/20 | 0.52 |
| ▸ | VIPR1 | P32241 | 2/20 | 0.52 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.51 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31243850 | 1.00 | IL23R (0.52) | IL23RBACE1BACE2KISS1RVIPR2 | |
| SCHEMBL31634763 | 1.00 | IL23R (0.52) | IL23RBACE1BACE2KISS1RVIPR2 | |
| SCHEMBL31243882 | 0.97 | KISS1R (0.54) | IL23RKISS1ROPRM1OPRD1OPRK1 | |
| SCHEMBL31243883 | 0.95 | BACE1 (0.56) | BACE1BACE2VIPR2OPRD1 | |
| SCHEMBL31243868 | 0.94 | OPRD1 (0.54) | BACE1BACE2KISS1ROPRM1OPRD1 | |
| SCHEMBL31243891 | 0.94 | OPRD1 (0.54) | BACE1BACE2KISS1ROPRM1OPRD1 | |
| SCHEMBL31243852 | 0.94 | OPRD1 (0.54) | BACE1BACE2KISS1ROPRM1OPRD1 | |
| SCHEMBL31243886 | 0.93 | KISS1R (0.55) | BACE1BACE2KISS1RVIPR2VIPR1 | |
| SCHEMBL31031570 | 0.92 | KISS1R (0.60) | IL23RKISS1ROPRL1OPRM1OPRD1 | |
| SCHEMBL29531061 | 0.92 | OPRD1 (0.57) | BACE1BACE2KISS1ROPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250263393-A1 | FAP INHIBITORS | SHANGHAI SINOTAU BIOTECH. CO., LTD (CN) | 2025-08-21 | — | — | US | disclosed |
| CN-120202191-A | Inhibitors of prostate specific membrane antigen and uses thereof | 上海先通生物科技有限公司 | 2025-06-24 | — | — | CN | disclosed |
| CN-119072472-A | FAP inhibitors | 上海先通生物科技有限公司 | 2024-12-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250263393-A1 | FAP INHIBITORS | FAP, APC, FIBP | IL23R 1563/4885BACE1 254/4885BACE2 238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.